80 results about "Lactococcus lactis subsp. lactis" patented technology

The invention belongs to the technical field of biological medicine, and discloses lactococcus lactis HX21473 and application thereof, the lactococcus lactis HX21473 is preserved in China General Microbiological Culture Collection Center (CGMCC) on January 20, 2025, and the preservation number is CGMCC NO.33476. The invention further discloses a preparation method of the lactococcus lactis HX21473. The invention provides a strain of lactococcus lactis HX21473 capable of efficiently expressing a foreign protein. The lactococcus lactis HX21473 has strong acid resistance, can be used as an oral vaccine live carrier, and promotes research, development and application of oral vaccines.

The invention belongs to the technical field of new energy materials, and particularly relates to a preparation method of a bamboo-based hard carbon sodium ion battery negative electrode material, which specifically comprises the following steps: (1) slicing, crushing, screening, sieving, drying and treating fresh bamboo under steam pressure to obtain bamboo powder; (2) bamboo powder and lactococcus lactis liquid are mixed and fermented, and after fermentation is completed, the bamboo powder and the lactococcus lactis liquid are washed to be neutral and dried; (3) placing the bamboo powder subjected to fermentation treatment in an inert atmosphere, heating, keeping constant temperature, and cooling to obtain a pre-carbonized sample; (4) soaking the pre-carbonized sample in a hydrochloric acid solution, continuously reacting, washing to be neutral, and drying; and (5) continuously heating the acid-washed and dried material in the step (4) in the inert atmosphere, carbonizing at a constant temperature, and cooling to obtain the final sodium-ion battery negative electrode material. The method disclosed by the invention has the advantages of remarkable environmental friendliness, low cost, simplicity and convenience in operation and the like; and the battery negative electrode material prepared by the method disclosed by the invention has excellent electrochemical performance.

The invention belongs to the technical field of biomedical treatment and biological fermentation, discloses a metagen composition for effectively inhibiting oral dental caries and application thereof, and aims to solve the problems of great side effect, weak effect and unknown mechanism of the existing dental caries prevention and treatment means. The composition is prepared by mixing a metagen 1 which is prepared by fermenting lactobacillus salivarius Postbio-YY with a metagen 2 which is prepared by fermenting lactococcus lactis Postbio-F3 and lactobacillus paracasei Postbio-P6 step by step. In the preparation process, the active ingredients are reserved by accurately controlling the fermentation pH, time and pasteurization parameters. The composition can be prepared into multiple dosage forms such as toothpaste and the like, can remarkably inhibit the growth of streptococcus mutans and destroy the thallus structure, inhibits biofilm and exopolysaccharide synthesis by down-regulating fimI, wcaJ and wcae genes, is safe and free of side effects, and provides an efficient scheme for decayed tooth prevention and treatment.

The application discloses a Vibrio harveyi oral vaccine and a preparation method and application thereof. The application uses a lactococcus lactis NZ9000 expression system, modifies transformation parameters, effectively expresses Vibrio harveyi OmpU protein, constructs a lactococcus lactis (NZ9000) engineering bacterium expressing Vibrio harveyi outer membrane protein (OmpU), develops an oral vaccine against Vibrio harveyi infection, aims to reduce the infection of economic animals in seawater aquaculture by oral administration, provides a new scheme for dealing with the harm of Vibrio harveyi infection and antibiotic resistance and the like, promotes the breeding of fry and fingerlings, and promotes the development of biological agriculture and related industries. The strategy is expected to overcome the problems of traditional injection vaccines, such as inconvenient operation and great stress, and can provide a new technical scheme for reducing the dependence of the aquaculture industry on antibiotics and promoting the establishment of a green and healthy breeding mode.

The invention discloses a method for improving yield of branched chain aldehyde of lactococcus lactis based on regulation and control of a luxS gene and application, and belongs to the field of system biology. Gene function verification and genome scale metabolic network model analysis are creatively combined, the phenotypic effect of the luxS gene is confirmed, and more importantly, the internal action mechanism of the luxS gene is disclosed from the system level, that is, the whole metabolic network flow is influenced by regulating and controlling multiple key enzymes such as transaminase, decarboxylase, dehydrogenase and decarboxylase. The invention reveals that the quorum sensing core gene luxS has a new function of regulating and controlling synthesis of branched chain aldehyde in lactococcus lactis for the first time, and an intercellular communication system is directly linked with production of specific flavor metabolites. The invention provides a brand-new and higher-level regulation target and thought for producing flavor substances by microbial fermentation, and gets rid of the limitation that only metabolic pathway terminal enzyme is singly modified traditionally.

The application discloses a beta-1,4-xylanase mutant and a construction method thereof, and comprises the following steps: constructing a beta-1,4-xylanase recombinant expression vector; introducing the recombinant vector pNZ8048-P5-XynA into a competent lactococcus lactis by using an electrotransformation technology to construct a wild-type expression vector; on the basis, designing and constructing a multi-site mutant recombinant plasmid by using a site-directed mutation method, wherein the eighth asparagine (Asn) of the beta-1,4-xylanase is mutated into tyrosine (Tyr), the 22nd serine (Ser) is mutated into proline (Pro), and the 59th alanine (Ala) is mutated into lysine (Lys); introducing the multi-site mutant recombinant plasmid into the competent lactococcus lactis to construct a heterologous expression strain of the mutant beta-1,4-xylanase (Mut-1); and stably obtaining the mutant xylanase beta-1,4-xylanase (Mut-1) with high activity by using a metal affinity chromatography (Ni 2+ ) method. The specific enzyme activity of the mutant reaches 1929.30±5.36 U / mg, and the optimal temperature is increased by 15 DEG C compared with that of the wild type.

A starter culture for the fermentation of a plant-based milk alternative is provided, which is particularly suitable for the production of a plant-based yogurt alternative. The starter culture comprises lactic acid bacteria isolated from legume plant material, especially pea plant material. Preferably, the starter culture comprises lactic acid bacteria of the species Lactobacillus rhamnosus and / or Lactococcus lactis subsp. cremoris.

The application provides a lactococcus lactis, a compound dairy product fermenting agent and application thereof, the lactococcus lactis has the functions of sweetening and flavoring, and is classified and named as lactococcus lactis Lactococcus lactis The strain has significant sweetening and flavoring characteristics, exhibits strong fructo-oligosaccharide (FOS) and acetaldehyde generation capacity in the fermentation process, can provide endogenous sweet taste and aroma flavor substances for fermented milk, and significantly improves the taste and flavor of the fermented milk.The lactococcus lactis C15 is compounded with lactobacillus casei AU9077 and lactobacillus rhamnosus AU9260 to obtain a compound dairy product fermenting agent, which has a significant synergistic effect in releasing fructo-oligosaccharide, continuously provides stable endogenous sweetening effect for fermented milk, improves the quality of dairy products, and meets the needs of consumers for healthy and flavored dairy products.

A composition for use in treating or preventing colorectal cancer (CRC) comprising or a fraction of Lactococcus lactis supernatant having a molecular weight greater than 100 kDa which may be obtained by filtration through a 100 kDa molecular weight filter. The composition also comprises a physiologically acceptable excipient and the fraction may be a protein fraction of the L. lactis supernatant. The composition may be formulated for oral ingestion, a powder, liquid, paste, cream, tablet, capsule, or caplet or in a food or beverage item. Additionally, the composition may be formulated in a daily dosage. Also claimed is a kit for treating or preventing colorectal cancer wherein a first container comprises the fraction of L. lactis culture supernatant.

The invention belongs to the technical field of gene engineering, and particularly relates to an efficient electrotransformation method of lactococcus lactis BL19. According to the method disclosed by the invention, the electric shock conversion efficiency of the lactococcus lactis BL19 is remarkably improved, and a foundation is laid for genetic engineering transformation in the future.

The present invention relates to the strain Lactococcus lactis subsp. lactis CECT 31096, to its cellular components, metabolites, and secreted molecules, and to compositions comprising the above products, as well as to their uses as a medicament, preferably for the prevention and / or reduction of hypertension, or as a food composition or nutraceutical.

The present invention relates to a composition for treating, ameliorating and preventing liver diseases, comprising a Lactococcus lactis strain, amino acids, and a vitamin. Specifically, the present invention relates to a composition for treating, ameliorating and preventing fatty liver, comprising Lactococcus lactis KF140, tryptophan, histidine, and vitamin E.

A composition for use in treating or preventing colorectal cancer (CRC) comprising indole-3-Iactic acid (ILA) or an aminopeptidase produced by Lactococcus lactis, the aminopeptidase having a molecular

The application discloses a lactococcus lactis GL-1 and application of the lactococcus lactis GL-1 in Apostichopus japonicus breeding, and belongs to the field of aquatic beneficial microorganisms and application technologies thereof. The lactococcus lactis GL-1 is preserved in the China General Microbiological Culture Collection Center on September 16, 2025, and the preservation number is CGMCC No. 35938, and the lactococcus lactis GL-1 is isolated from traditional fermented food doubansauce. The strain can well adapt to different environments, and can be used for preparing an Apostichopus japonicus feed additive. When the number of viable lactococcus lactis GL-1 in the feed is greater than or equal to 1x10 8 CFU / g, the low-salt stress resistance of the Apostichopus japonicus can be significantly enhanced, the survival rate and growth performance are improved, the intestinal flora structure is improved, the colonization of beneficial bacteria is promoted, and immune-related pathways such as the Wnt signal pathway are activated, so that the health level of the Apostichopus japonicus is improved from multiple aspects. A safe and effective microbial solution is provided for solving the low-salt stress problem in the Apostichopus japonicus breeding.

The application discloses a Leuconostoc intestini and Lactococcus lactis composition and application, belongs to the field of microbial pharmacy, and relates to application of a Leuconostoc intestini and Lactococcus lactis composition to preparation of a drug for treating pulmonary fibrosis diseases; wherein the quantity of the Leuconostoc intestini and the Lactococcus lactis in the composition is equal in terms of colony forming units. Experimental results show that the Leuconostoc intestini and the Lactococcus lactis can effectively improve pulmonary fibrosis when being intervened alone or in combination. It is known to those skilled in the art that excessive deposition of collagen fibers is a core feature of pulmonary fibrosis diseases, and the Leuconostoc intestini and the Lactococcus lactis have a synergistic effect of inhibiting the content of lung tissue collagen in pulmonary fibrosis. Therefore, the Leuconostoc intestini and the Lactococcus lactis composition has a prospect of being developed into a drug for treating pulmonary fibrosis diseases (including idiopathic pulmonary fibrosis and secondary pulmonary fibrosis).

The application belongs to the technical field of biological gene engineering, and discloses a lactococcus lactis carrier oral vaccine for producing enterotoxigenic escherichia coli F18 pilus type and application. Four lactococcus lactis antigen surface display strains are prepared, and are mixed to perform oral immunization. The oral immunization mode is convenient to operate, avoids the stress reaction caused by injection immunization on animals, and greatly improves the immunization effect, so that the diarrhea caused by enterotoxigenic escherichia coli on piglets can be effectively prevented. 50 The application is an oral escherichia coli vaccine, and mouse immunization challenge experiment shows that all the mice can survive under the challenge dose of LD , and piglet immunization challenge experiment shows that the piglets can be 100% protected from diarrhea, which shows that the immunization group has effective mucosal immune protection ability.

The invention relates to a sensitive skin micro-ecological balance-oil control and acne removal composition and application thereof. The composition is prepared from the following components: lactococcus lactis / phellinus pharmacologically fermented product filtrate, lactobacillus / black mustard seed fermented product extract, citrus fruit extract and trifolium pretense flower extract. The weight ratio of the lactococcus lactis / phellinus pharmacologically fermented product filtrate to the lactobacillus / black mustard seed fermented product extract to the citrus fruit extract to the trifolium pretense flower extract is (0.1-8): (0.001-0.1): (0.001-0.2): (0.01-3), and the composition constructs a four-stage synergistic mechanism of flora regulation, barrier repair, oil control and fat suppression, anti-inflammation and soothing; the limitation of a single target spot in the traditional technology is broken through, and an efficient, safe and multi-dimensional regulation and control comprehensive solution is provided for oily sensitive skin micro-ecological balance.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

The application discloses a kind of 7 kinds of composition containing probiotic and its preparation method of drinkable yoghurt, belong to microbial fermentation technical field.Composition includes the combination of 2 kinds of lactic acid bacteria and 7 kinds of probiotic, lactic acid bacteria is the combination of lactococcus lactis subsp cremoris and lactococcus lactis subsp lactis;Probiotic is the combination of lactobacillus bulgaricus, streptococcus thermophilus, bifidobacterium lactis, lactobacillus acidophilus, paracasei, lactobacillus rhamnosus and bifidobacterium infantis.The composition can provide the required probiotic for children, young people, old people respectively, and in the new preparation method developed additionally, through the combination of lactic acid bacteria and probiotic, lactase pretreatment and two-step inoculation fermentation process in fermentation stage, twice post-ripening process can effectively guarantee the acidity of composition fermentation moderate, improve the stability of composition system and taste.The overall additive of the obtained product is zero addition and the flavor is excellent and high stability.

Provided are methods for preventing or treating a chronic pain in a subject that includes administering an effective amount of a composition of Lactococcus lactis DSM 27109 to the subject.

The invention relates to the technical field of dairy product processing, in particular to a fried cheese formula and a preparation method thereof, and the fried cheese formula comprises the following components by mass: raw milk subjected to standardization treatment, animal type chymosin, a leavening agent, calcium chloride and edible salt; the animal type chymosin is a mixture of rennase and bovine pepsase according to a mass ratio of 70: 30, the activity of the chymosin is greater than or equal to 890 IMCU / g, the addition amount of the chymosin is 43 g / t, and the chymosin is used for improving the curding efficiency and the structural stability; the leavening agent is lactococcus lactis subsp.cremoris and lactococcus cremoris, the addition amount of the leavening agent is 4D / t, and the leavening agent is used for increasing the flavor and fragrance of the product; the addition amount of the calcium chloride is 70g / t, and the calcium chloride is used for strengthening protein network crosslinking. According to the invention, the raw milk is standardized, so that the quality stability of the product is obviously improved; the thermal stability is optimized, and the eating scene is expanded; and strains capable of generating flavor substances are added, so that flavor levels are rich, the mouth feel is fine and elastic, and the eating experience is upgraded.

The invention relates to the technical field of microbial fermentation, in particular to casei paracasei SITRS-0034, culture thereof and application of the casei paracasei SITRS-0034 in preparation of a compound aroma-producing leavening agent. According to the present invention, the Lactobacillus paracasei SITRS-0034 and the Lactococcus lactis SITRS-0011 are adopted to be matched so as to obtain the compound aroma production fermentation agent, and the compound aroma production fermentation agent can be used to prepare the aroma production fermentation agent, fermented milk fat products produced by fermentation of the compound aroma-producing leavening agent are rich in aroma and excellent in texture; specifically, when the lactobacillus plantarum is used for fermenting yoghurt oil, the contents of butanedione and acetoin in the obtained yoghurt oil respectively reach 1944 mu g / kg and 1648 mu g / kg, and the lactobacillus plantarum is rich in milk flavor and relatively high in overall score; when the fermented butter is used for fermenting butter, the obtained fermented butter has rich flavor, and the sensory effect is improved.

This invention belongs to the field of bioengineering technology, specifically relating to a gene for efficiently expressing thymosin α1 (Tα1), recombinant lactic acid bacteria, and their applications. This invention provides a Tα1 encoding gene specifically optimized for *Lactococcus lactis* NZ9000, which significantly improves expression efficiency in the host through full-sequence codon adaptation. This gene was cloned into the vector pNZ8148-M, constructing the recombinant expression plasmid NZ9000 / pNZ8148-M. usp45 + T α1 The strain was successfully transformed into the host bacterium NZ9000, yielding recombinant lactic acid bacteria NZ9000 / pNZ8148-M. usp45 + Tα1 This recombinant strain can efficiently secrete the Tα1 fusion protein USP under Nisin induction. 45 +Tα1, the protein is digested in vitro by enterokinase to release active Tα1. The Tα1 produced by the method of this invention has high yield, high purity, high biological activity and excellent safety, providing a new technical platform for the low-cost, large-scale and safe production of Tα1.

The application provides a direct-vat yogurt fermenting agent and a preparation method, and belongs to the technical field of fermentation. The direct-vat yogurt fermenting agent comprises fermenting strains, the fermenting strains are composed of lactococcus lactis, lactobacillus fermentum and lactobacillus delbrueckii, the fermenting strains are inoculated into a fermentation medium after being activated respectively to obtain a fermentation liquor for preparing the direct-vat yogurt fermenting agent; the inoculation adopts seed liquid mixing inoculation, the seed liquid is obtained by activating the lactococcus lactis, the lactobacillus fermentum and the lactobacillus delbrueckii respectively, and the volume ratio of the seed liquids of the lactococcus lactis, the lactobacillus fermentum and the lactobacillus delbrueckii is 1-2:2-4:10-12. The direct-vat yogurt fermenting agent is prepared by compounding the existing technical strains, the direct-vat yogurt fermenting agent has lower requirements for the environment, faster fermentation speed, good ability of controlling miscellaneous bacteria, high content of lactic acid bacteria in the prepared product, and is of great significance for industrial production.

This invention discloses a walnut oil-based yogurt with a milk skin and its preparation method, belonging to the field of dairy product technology. The walnut oil-based yogurt contains the following ingredients in parts by weight: 100 parts fresh milk, 3-7 parts walnut oil, 0.5-1.5 parts enzymatically hydrolyzed lecithin, and may also contain 4-8 parts protein powder, 6-10 parts cheese powder, 4-8 parts egg yolk powder, and 5-7 parts white sugar. The preparation method includes: heating the fresh milk and adding protein powder, cheese powder, and other ingredients; heating again and adding the remaining white sugar; emulsifying the walnut oil and lecithin at 55-65℃; homogenizing and sterilizing; cooling to 40-45℃ and inoculating with *Lactobacillus casei* and *Lactococcus lactis* subsp. *lactococcus*; fermenting at 30-35℃ for 10-14 hours, and then refrigerating at 2-6℃ for 16-24 hours to form a milk skin layer. The yogurt prepared by this invention has a unique milk skin layer, a rich taste, and high nutritional value.

The invention discloses a high-salt-resistant cheese composite leavening agent and application thereof, and belongs to the technical field of fermented dairy products. The strains in the high-salt-resistant cheese compound leavening agent comprise leuconostoc mesenteroides subsp. Mesenteroides JMCC0041, lactococcus lactis subsp. Cremoris JMCC0035, lactococcus lactis subsp. Lactis JMCC0036 and streptococcus salivarius subsp. Thermophilus JMCC16, the leavening agent is resistant to high-salt conditions, the fermentation speed is appropriate, when the leavening agent is used for fermenting cheese products, the obtained fermentation products are low in peculiar smell and bitter taste, and the fermentation effect is good. The content of butanedione in the cheese is high and appropriate, and the cream fragrance is prominent. The method is suitable for cheese fermentation production.

The invention discloses a lactococcus lactis recombinant bacterium for expressing cyclic diadenylate and application of the lactococcus lactis recombinant bacterium. The recombinant bacterium is obtained by carrying out multi-gene synergistic modification on lactococcus lactis. The method specifically comprises the following steps: carrying a homologous diadenylate cyclase (DAC) gene, overexpressing glycolysis key enzyme phosphofructokinase (PFK), knocking out a phosphodiesterase (PDE) gene for degrading c-di-AMP, and knocking out a lactic dehydrogenase (ldh) gene. Through the synergistic effect of the transformation, the supply of the precursor ATP is remarkably improved, and the degradation of the c-di-AMP and the accumulation of lactic acid byproducts are reduced, so that the efficient expression of the c-di-AMP is realized.

The application is directed to a method to manufacture pasta-filata cheese based on cultures comprising or consisting of either 1) at least a galactose-positive Streptococcus thermophilus strain as defined herein or 2) at least a Streptococcus thermophilus strain and a Lactococcus lactis strain, and to a stretched curd or cheese produced by this method. The application is also directed to a culture or kit-of-part comprising or consisting of a) a galactose-positive Streptococcus thermophilus strain as defined herein, and b) Lactococcus strain(s) and / or Lactobacillus helveticus strain(s).

The present invention relates to a novel lactic acid bacterium Lactococcus lactis P91 KCCM 13447P, Bifidobacterium animalis P97 KCCM 13448P, or a mixture thereof, and a use thereof. The strain and the mixture thereof, according to the present invention, can be effectively used for preventing, treating or alleviating neuropsychiatric diseases or inflammatory diseases.